These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8953099)

  • 1. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW; Wexler HM
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
    Hecht DW; Osmolski JR
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolone activity against anaerobes.
    Appelbaum PC
    Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolone activity against anaerobes: microbiological aspects.
    Appelbaum PC
    Drugs; 1995; 49 Suppl 2():76-80. PubMed ID: 8549420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
    Goldstein EJ
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S377-81. PubMed ID: 8324151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
    Goldstein EJ; Citron DM; Warren Y; Tyrrell K; Merriam CV
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
    Goldstein EJ
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
    Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
    Barry AL; Fuchs PC; Citron DM; Allen SD; Wexler HM
    J Antimicrob Chemother; 1993 Jun; 31(6):893-900. PubMed ID: 8395494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of DU-6859a against anaerobic bacteria.
    Wexler HM; Molitoris E; Reeves D; Finegold SM
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
    Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
    Antimicrob Agents Chemother; 1997 May; 41(5):1193-5. PubMed ID: 9145900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
    Aldridge KE; Ashcraft D; Bowman KA
    Antimicrob Agents Chemother; 1997 Feb; 41(2):484-7. PubMed ID: 9021215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.